Original (D614) and variants of concern
InvivoGen offers a collection of plasmids specifically designed for pseudotyping lentiviral particles with the full-length SARS-CoV-2 Spike (S) protein. For optimal expression, the spike gene has been codon-optimized and the C‑terminal ER-retention signal has been removed.
Various SARS-CoV-2 variants are available:
- Original | Wuhan (Clade 19)
- G614 variant | (Clade 20)
- Alpha | B.1.1.7 variant | United Kingdom (Clade 20I)
- Beta | B.1.351 variant | South Africa (Clade 20H)
- Epsilon | B.1.429 variant | California (Clade 21C)
- Gamma | P.1 variant | Brazil (Clade 20J)
- Iota | B.1.526 variant | New York (Clade 21F)
- Kappa | B.1.617.1 variant | India (Clade 21B)
- Delta | B.1.617.2 variant | India (Clade 21A)
- Lambda | C.37 variant | Peru (Clade GR/452Q.V1)
- Mu | B.1.621 variant | Colombia (Clade 21H)
- Omicron | B.1.1.529/BA.1 variant | South Africa (Clade 21K)
- Omicron | BA.2 variant | South Africa (Clade 21L)
- Omicron | BA.4 & BA.5 variants | South Africa (Clades 22A & 22B)
- Omicron | BQ.1.1 variant | Nigeria (Clade GRA)
- Omicron | XBB.1.5 variant | USA (Clade GRA)
- Omicron | JN.1 variant | USA (Clade GRA)
More information on SARS-CoV-2 variants
Application
Pseudotyped particle production involves the co-transfection of 293T cells with a reporter protein vector (e.g. GFP), one or several plasmids encoding the necessary lentiviral proteins, and InvivoGen's pseudotyping pLV-Spike plasmids. The transfected cells produce SARS‑CoV‑2 Spike (S)‑pseudotyped lentiviral particles, which can then be purified and used to infect permissive cells, such as ACE2‑expressing HEK293-derived cells and ACE2‑TMPRSS2‑expressing A549-derived cells.
